ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2766

The Predictive Value of Patient’s and Evaluator’s Global Assessment and Tender and Swollen Joint Count Differences on Treatment Efficacy in Psoriatic Arthritis: Data from a Longitudinal Multicenter Study

Brigitte Michelsen1,2, Eirik K Kristianslund1, Hilde B Hammer3, Karen M Fagerli1, Elisabeth Lie1, Glenn Haugeberg4,5 and Tore K Kvien1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 3Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, 5Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: psoriatic arthritis and remission

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Discordance between patient’s and physician’s evaluation of disease activity may be challenging in psoriatic arthritis (PsA). The potential impact of such a difference on treatment outcome is to date unexplored. In this study we aimed to investigate the predictive value of baseline patient’s and evaluator’s global assessment difference (deltaPEG) as well as tender and swollen joint count difference (deltaTSJ) for achievement of remission in PsA.

Methods: From the prospective, multicenter NOR-DMARD study we included PsA patients starting first-time tumor necrosis factor inhibitors (TNFi) and DMARD naïve patients starting methotrexate between 2000 and 2012. The predictive value of deltaPEG and deltaTSJ on remission, defined by various criteria, was explored in prespecified logistic regression models adjusted for age, sex, disease duration and smoking.

Results: A total of 1236 PsA patients were included (mean (SD) age 48.3 (12.4) years, disease duration 4.8 (7.5) years, 48.4% females, 29.8% current smokers, baseline mean (SD) evaluator’s global assessment 34.1 (16.6), patient’s global assessment 51.1 (22.6), deltaPEG 17.0 (24.3), median (IQR) 32 tender joint count 5 (8), 32 swollen joint count 3 (5), deltaTSJ 1 (5), DAS28ESR 4.2 (1.3), baseline median (IQR) SDAI 16.9 (12.8), CDAI 8.6 (10.3), modified DAPSA 21.0 (14.1) (including 32 instead of the original 66/68 joint count). Bar charts of percentages of PsA patients in remission at 6 months according to categorization of deltaPEG and deltaTSJ into quartiles showed reduced probability of remission with increasing deltaPEG and deltaTSJ (unadjusted values; figures).

Baseline deltaPEG and deltaTSJ predicted DAS28<2.6, SDAI≤3.3, CDAI≤2.8, ACR/EULAR Boolean and DAPSA<4 remission after 3 and 6 months, except for deltaPEG and DAS28 remission at 6 months (adjusted analyses; table).  

  Months DAS28ESR < 2.6 SDAI ≤ 3.3 CDAI ≤ 2.8 ACR/EULAR Boolean DAPSA < 4
deltaTSJ 3 0.92 [0.89, 0.96] p<0.001 0.91 [0.86, 0.95] p<0.001 0.93 [0.89, 0.97] p=0.001 0.93 [0.88, 0.98] p=0.004 0.91 [0.86, 0.95] p<0.001
6 0.94 [0.90, 0.97] p=0.001 0.94 [0.90, 0.98] p=0.003 0.93 [0.89, 0.97] p=0.001 0.92 [0.88, 0.97] p=0.002 0.93 [0.89, 0.98] p=0.002
deltaPEG 3 0.89 [0.84, 0.94] p<0.001 0.98 [0.98, 0.99] p<0.001 0.99 [0.98, 0.995] p=0.001 0.99 [0.98, 0.99] p=0.001 0.99 [0.98, 0.995] p=0.002
6 1.00 [0.99, 1.01] p=0.94 0.99 [0.98, 0.995] p=0.001 0.99 [0.98, 0.99] p<0.001 0.98 [0.97, 0.99] p<0.001 0.99 [0.98, 0.99] p=0.001

Data are presented as OR [95% CI]  

Conclusion: DeltaPEG and deltaTSJ constitute new and important predictors of treatment efficacy in PsA and may be considered in the shared decision of a target in a treat-to-target strategy.  


Disclosure: B. Michelsen, None; E. K. Kristianslund, None; H. B. Hammer, None; K. M. Fagerli, None; E. Lie, None; G. Haugeberg, None; T. K. Kvien, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, Novartis, Orion Pharma, Prizer, Sandoz, UCB, 5.

To cite this abstract in AMA style:

Michelsen B, Kristianslund EK, Hammer HB, Fagerli KM, Lie E, Haugeberg G, Kvien TK. The Predictive Value of Patient’s and Evaluator’s Global Assessment and Tender and Swollen Joint Count Differences on Treatment Efficacy in Psoriatic Arthritis: Data from a Longitudinal Multicenter Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-predictive-value-of-patients-and-evaluators-global-assessment-and-tender-and-swollen-joint-count-differences-on-treatment-efficacy-in-psoriatic-arthritis-data-from-a-longitudina/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-predictive-value-of-patients-and-evaluators-global-assessment-and-tender-and-swollen-joint-count-differences-on-treatment-efficacy-in-psoriatic-arthritis-data-from-a-longitudina/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology